

Didier Samuel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2146212/publications.pdf>

Version: 2024-02-01

544
papers

30,791
citations

3731

89
h-index

6131

159
g-index

572
all docs

572
docs citations

572
times ranked

19400
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis and Cannabinoid Research, 2022, 7, 677-689.	2.9	6
2	Prognostic impact of surgical margins for hepatocellular carcinoma according to preoperative alpha-fetoprotein level. Hpb, 2022, 24, 848-856.	0.3	4
3	State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver International, 2022, 42, 288-298.	3.9	5
4	Impact of COVID-19 in patients awaiting liver transplantation. Liver International, 2022, 42, 256-257.	3.9	1
5	Liver stiffness-based model predicts hepatic venous pressure gradient in patients with liver disease. Hpb, 2022, 24, 1796-1803.	0.3	5
6	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	2.9	6
7	A systematic review of auxiliary liver transplantation of small-for-size grafts in patients with chronic liver disease. JHEP Reports, 2022, 4, 100447.	4.9	3
8	Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study. United European Gastroenterology Journal, 2022, 10, 396-408.	3.8	7
9	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. Journal of Cannabis Research, 2022, 4, .	3.2	1
10	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101459.	1.5	4
11	Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study. Digestive Diseases and Sciences, 2021, 66, 2107-2117.	2.3	1
12	Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept. Journal of Hepatology, 2021, 74, 661-669.	3.7	35
13	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
14	Management of Transplant Patients Infected with HCV. , 2021, , 153-173.		0
15	Systemic inflammation and liver cirrhosis complications: Driving or secondary event? How to square the circle?. Journal of Hepatology, 2021, 74, 508-510.	3.7	5
16	Mild increases in plasma creatinine after intermediate to high-risk abdominal surgery are associated with long-term renal injury. BMC Anesthesiology, 2021, 21, 135.	1.8	2
17	Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score. Journal of Hepatology, 2021, 74, 1325-1334.	3.7	28
18	Hepatic Arteriovenous Malformation: The Search for a PTEN Mutation!. Hepatology, 2021, 74, 1121-1123.	7.3	1

#	ARTICLE	IF	CITATIONS
19	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 583-605.	3.7	27
20	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. <i>Journal of Hepatology</i> , 2021, 75, S178-S190.	3.7	30
21	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	4.9	6
22	Donor HLA Class 1 Evolutionary Divergence Is a Major Predictor of Liver Allograft Rejection. <i>Annals of Internal Medicine</i> , 2021, 174, 1385-1394.	3.9	11
23	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	3.7	96
24	Mass Spectrometry-Based Proteomics Reveal Alcohol Dehydrogenase 1B as a Blood Biomarker Candidate to Monitor Acetaminophen-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11071.	4.1	1
25	Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2020, 72, 965-981.	7.3	159
26	Comparative analysis of outcomes after liver resection and liver transplantation for early stages hepatocellular carcinoma in HIV-infected patients. An intention-to-treat analysis. <i>Hpb</i> , 2020, 22, 900-910.	0.3	0
27	Liver Resection for Early Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2020, 272, 820-826.	4.2	19
28	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	4.9	86
29	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
30	Indocyanine Green Fluorescence Imaging to Predict Graft Survival After Orthotopic Liver Transplantation: A Pilot Study. <i>Liver Transplantation</i> , 2020, 26, 1263-1274.	2.4	9
31	Sofosbuvir+Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020, 27, 964-973.	2.0	5
32	Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. <i>Liver International</i> , 2020, 40, 1853-1859.	3.9	9
33	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020, 73, 130-139.	3.7	78
34	Spleen volumetry and liver transient elastography: Predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. <i>Surgery</i> , 2020, 168, 17-24.	1.9	8
35	Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease. <i>Neurology</i> , 2020, 94, e2189-e2202.	1.1	36
36	Cyclin-dependent kinase inhibitors p21 and p27 function as critical regulators of liver regeneration following 90% hepatectomy in the rat. <i>World Journal of Hepatology</i> , 2020, 12, 1198-1210.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Prognostic factors of survival in <scp>HIV</scp>/<scp>HCV</scp> coâ€infecte patients with hepatocellular carcinoma: The <scp>CARCINOVIC</scp> Cohort. Liver International, 2019, 39, 136-146.	3.9	9
38	Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. European Journal of Clinical Pharmacology, 2019, 75, 1555-1563.	1.9	0
39	A Critical Review of MELD as a Reliable Tool for Transplant Prioritization. Seminars in Liver Disease, 2019, 39, 403-413.	3.6	41
40	Management of Fulminant Hepatitis B. Current Infectious Disease Reports, 2019, 21, 25.	3.0	18
41	Impact of the new MELDâ€based allocation system on waiting list and postâ€transplant survivalâ€a cohort analysis using the French national <scp>CRISTAL</scp> database. Transplant International, 2019, 32, 1061-1073.	1.6	13
42	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
43	Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2019, 26, 2568-2576.	1.5	40
44	Prevention of decompensation in cirrhosis: a new youth for Î² blockers. Lancet, The, 2019, 393, 1571-1572.	13.7	4
45	Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. Journal of Hepatology, 2019, 70, 1297-1300.	3.7	2
46	Approaches for patients with very high MELD scores. JHEP Reports, 2019, 1, 53-65.	4.9	17
47	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infectious Diseases, 2019, 19, 300.	2.9	5
48	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	13.7	449
49	HCV-positive organ transplants in HCV-negative recipients. The Lancet Gastroenterology and Hepatology, 2019, 4, 745-747.	8.1	1
50	Evaluation of a micro-spectrometer for the real-time assessment of liver graft with mild-to-moderate macrosteatosis: A proof of concept study. Journal of Hepatology, 2019, 70, 423-430.	3.7	16
51	Reply to: â€œAcute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?â€ Journal of Hepatology, 2019, 70, 566-567.	3.7	2
52	Liver transplantation in patients with liver failure related to exertional heatstroke. Journal of Hepatology, 2019, 70, 431-439.	3.7	17
53	Safety of sofosbuvirâ€based regimens after liver transplantation: longitudinal assessment of renal function in the prospective <scp>ANRS</scp> CO23 CUPILT study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1682-1689.	3.7	7
54	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology, 2018, 68, 1181-1190.	3.7	372

#	ARTICLE	IF	CITATIONS
55	The impact of treatment of hepatitis C with <scp>DAA</scp>s on the occurrence of <scp>HCC</scp>. Liver International, 2018, 38, 139-145.	3.9	109
56	Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France. Journal of Antimicrobial Chemotherapy, 2018, 73, 41-51.	3.0	39
57	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Clinical Infectious Diseases, 2018, 66, 1013-1018.	5.8	43
58	Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation. Transplantation, 2018, 102, 119-126.	1.0	18
59	Prospective validation of transient elastography for staging liver fibrosis in patients undergoing hepatectomy and liver transplantation. Journal of Hepatology, 2018, 68, 199-200.	3.7	10
60	Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis. Gastroenterology, 2018, 154, 1009-1023.e14.	1.3	107
61	Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant. Hepatology, 2018, 67, 86-96.	7.3	44
62	Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 253-260.	3.0	13
63	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". Journal of Hepatology, 2018, 69, 1397-1398.	3.7	2
64	Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal of Hepatology, 2018, 69, 810-817.	3.7	199
65	Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Medicine, 2018, 16, 113.	5.5	72
66	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". Journal of Hepatology, 2018, 69, 550-551.	3.7	2
67	Prognosis of ALF of unknown cause: results of the French multicentre prospective HASIPRO study. Journal of Hepatology, 2018, 68, S68-S69.	3.7	0
68	Reply to: "Mortality due to immunotherapy related hepatitis". Journal of Hepatology, 2018, 69, 978-979.	3.7	0
69	EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. Journal of Hepatology, 2017, 66, 1047-1081.	3.7	601
70	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. Transplantation, 2017, 101, S1-S56.	1.0	217
71	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation, 2017, 101, 945-955.	1.0	76
72	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation, 2017, 101, 956-967.	1.0	44

#	ARTICLE	IF	CITATIONS
73	HCV and HEV recurrence after liver transplantation: one antiviral therapy for two viruses. <i>Transplant International</i> , 2017, 30, 318-319.	1.6	10
74	Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms. <i>Transplantation</i> , 2017, 101, 1830-1837.	1.0	32
75	SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, S85-S86.	3.7	28
76	Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. <i>Journal of Hepatology</i> , 2017, 67, 708-715.	3.7	276
77	Treatment and prognosis of acute severe autoimmune hepatitis. <i>Journal of Hepatology</i> , 2017, 66, S4.	3.7	7
78	Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. <i>Liver International</i> , 2017, 37, 1869-1876.	3.9	22
79	Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2017, 49, e63.	0.9	0
80	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017, 67, 585-602.	3.7	71
81	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017, 65, 1683-1692.	7.3	68
82	A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. <i>Liver Transplantation</i> , 2017, 23, 143-154.	2.4	132
83	Immunotherapy in liver transplantation. <i>Journal of Hepatology</i> , 2017, 67, 874-875.	3.7	7
84	Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. <i>American Journal of Transplantation</i> , 2017, 17, 2869-2878.	4.7	6
85	Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3 & 6). <i>Journal of Hepatology</i> , 2017, 66, S529-S530.	3.7	1
86	Feasibility of anti-HCV direct acting anti-viral agents in French prison settings. <i>Journal of Hepatology</i> , 2017, 66, S743.	3.7	1
87	Apico-basal polarity in epithelial cell morphogenesis and liver pathogenesis. <i>Journal of Hepatology</i> , 2017, 66, S317.	3.7	0
88	Factors associated with tumor recurrence after liver transplantation for hepatocellular carcinoma: prospective cohort on 371 patients. <i>Journal of Hepatology</i> , 2017, 66, S200.	3.7	0
89	Cutting out the roots of acute hepatitis C. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 125-127.	9.1	0
90	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 56-65.	1.5	0

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	3.7	100
92	Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). <i>Antiviral Therapy</i> , 2016, 21, 195-205.	1.0	18
93	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. <i>World Journal of Gastroenterology</i> , 2016, 22, 4547.	3.3	12
94	A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases. <i>PLoS ONE</i> , 2016, 11, e0150733.	2.5	8
95	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 150, 256-258.	0.8	12
96	Intention-to-treat analysis of percutaneous endovascular treatment of hepatic artery stenosis after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 923-933.	2.4	35
97	Repeat liver retransplantation: rationale and outcomes. <i>Clinical Transplantation</i> , 2016, 30, 312-319.	1.6	16
98	Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus. <i>Transplantation</i> , 2016, 100, 1705-1713.	1.0	14
99	Liver Transplantation in Severe Neurological Forms of Wilson Disease; The French Experience. <i>Journal of Hepatology</i> , 2016, 64, S153.	3.7	2
100	Neuroinflammation in liver disease: sessional talks from ISHEN. <i>Metabolic Brain Disease</i> , 2016, 31, 1339-1354.	2.9	8
101	Optimum timing of treatment for hepatitis C infection relative to liver transplantation. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 165-172.	8.1	18
102	Single-Nucleotide Resolution Mapping of Hepatitis B Virus Promoters in Infected Human Livers and Hepatocellular Carcinoma. <i>Journal of Virology</i> , 2016, 90, 10811-10822.	3.4	27
103	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 957-966.	3.7	35
104	News and challenges in the treatment of hepatitis C in liver transplantation. <i>Liver International</i> , 2016, 36, 34-42.	3.9	16
105	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. <i>Hepatology</i> , 2016, 64, 1049-1056.	7.3	106
106	Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1432-1441.	5.3	40
107	Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection. <i>Transplantation</i> , 2016, 100, 1507-1512.	1.0	23
108	Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 1367-1378.	2.4	32

#	ARTICLE	IF	CITATIONS
109	Withdrawal of posttransplant hepatitis B virus prophylaxis: A blind test. <i>Liver Transplantation</i> , 2016, 22, 1183-1185.	2.4	3
110	Does Multiorgan Failure Impact Prognosis of Liver Transplantation in Patients with End-Stage Liver Disease? Results of a French Retrospective Multicenter Case-Control Study. <i>Journal of Hepatology</i> , 2016, 64, S537.	3.7	1
111	Are the Early Quality of Life Benefits Sustained Long-Term after Liver Transplantation? a 10-Year Longitudinal Diagnosis Stratified Evaluation. <i>Journal of Hepatology</i> , 2016, 64, S552-S553.	3.7	0
112	SOF/VEL for 12 Weeks Results in High SVR12 Rates in Subjects with Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy from the Astral-1, Astral-2 and Astral-3 Studies. <i>Journal of Hepatology</i> , 2016, 64, S787-S788.	3.7	4
113	Dynamic outcome prediction for paracetamol-related acute liver failure. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 177-178.	8.1	0
114	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. <i>Transplantation</i> , 2016, 100, 2129-2137.	1.0	25
115	Multimodality Imaging of Cardiac Transthyretin Amyloidosis 16 Years After a Domino Liver Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 2208-2212.	4.7	9
116	Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma. <i>Journal of Translational Medicine</i> , 2016, 14, 17.	4.4	17
117	New perspectives for preventing hepatitis C virus liver graft infection. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 735-745.	9.1	41
118	Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT study. <i>Journal of Hepatology</i> , 2016, 65, 711-718.	3.7	72
119	Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. <i>Journal of Translational Medicine</i> , 2016, 14, 9.	4.4	16
120	Pros and Cons: Usage of organs from donors infected with hepatitis C virus – Revision in the direct-acting antiviral era. <i>Journal of Hepatology</i> , 2016, 64, 226-231.	3.7	49
121	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 685-697.	9.1	402
122	Quality of life 10 years after liver transplantation: The impact of graft histology. <i>World Journal of Transplantation</i> , 2016, 6, 703.	1.6	11
123	Hepatitis B Recurrence: Major Milestones and Current Status. , 2016, , 13-34.		0
124	Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1321-1334.	1.0	50
125	P0034 : Good outcome of patients transplanted with meld score greater than 30: Paul-brousse hospital experience. <i>Journal of Hepatology</i> , 2015, 62, S304.	3.7	0
126	P0137 : Safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation. Analysis from a French multicenter, open-label study (ANRS HC29 bocepretransplant). <i>Journal of Hepatology</i> , 2015, 62, S352-S353.	3.7	0

#	ARTICLE	IF	CITATIONS
127	P0150 : Liver cirrhosis is independently associated with mortality in patients with bacterial endocarditis: Results of a case control multicenter study of 202 cases. <i>Journal of Hepatology</i> , 2015, 62, S358.	3.7	0
128	Changing outcomes in acute liver failure: Can we transplant only the ones who really need it?. <i>Liver Transplantation</i> , 2015, 21, S36-S38.	2.4	6
129	Infectious complications after liver transplantation in human immunodeficiency virus-infected recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 662-670.	1.7	6
130	Liver metastases from meningeal hemangiopericytoma. <i>Liver International</i> , 2015, 35, 2337-2337.	3.9	4
131	Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. <i>Hepatology</i> , 2015, 62, 179-187.	7.3	36
132	Personalized Adapted Physical Activity Before Liver Transplantation. <i>Transplantation</i> , 2015, 99, 145-150.	1.0	98
133	Liver Transplantation for Hereditary Transthyretin Amyloidosis. <i>Transplantation</i> , 2015, 99, 1847-1854.	1.0	257
134	Spontaneous Splenorenal Shunt in Liver Transplantation. <i>Transplantation</i> , 2015, 99, 2576-2585.	1.0	34
135	Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. <i>Viruses</i> , 2015, 7, 5155-5168.	3.3	21
136	The Reg3 β (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure. <i>PLoS ONE</i> , 2015, 10, e0125584.	2.5	13
137	Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?. <i>PLoS ONE</i> , 2015, 10, e0138091.	2.5	38
138	Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. <i>Liver International</i> , 2015, 35, 1872-1876.	3.9	19
139	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen: The ANRS CO20-CUPIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450.	1.5	5
140	Quantitative Assessment of Liver Steatosis on Tissue Section Using Infrared Spectroscopy. <i>Gastroenterology</i> , 2015, 148, 295-297.	1.3	22
141	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015, 62, 1047-1055.	3.7	76
142	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	3.7	289
143	The implementation of an Intensive Care Information System allows shortening the ICU length of stay. <i>Journal of Clinical Monitoring and Computing</i> , 2015, 29, 263-269.	1.6	9
144	Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 322-327.	1.7	21

#	ARTICLE	IF	CITATIONS
145	G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial. Journal of Hepatology, 2015, 62, S187-S188.	3.7	67
146	O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. Journal of Hepatology, 2015, 62, S219-S220.	3.7	33
147	O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). Journal of Hepatology, 2015, 62, S251-S252.	3.7	10
148	LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*. Journal of Hepatology, 2015, 62, S258-S259.	3.7	26
149	LP19 : Early introduction of subcutaneous (S.C.) hepatitis B immunoglobulin (HBIg) provides effective prophylaxis for hepatitis B virus (HBV) reinfection after liver transplantation (TX). Journal of Hepatology, 2015, 62, S273.	3.7	0
150	LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather. Journal of Hepatology, 2015, 62, S278.	3.7	18
151	P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France. Journal of Hepatology, 2015, 62, S532-S533.	3.7	1
152	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. Journal of Hepatology, 2015, 62, S541-S542.	3.7	5
153	P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic. Journal of Hepatology, 2015, 62, S617-S618.	3.7	0
154	P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials. Journal of Hepatology, 2015, 62, S620-S621.	3.7	20
155	P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. Journal of Hepatology, 2015, 62, S623.	3.7	6
156	P0837 : Efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis. Journal of Hepatology, 2015, 62, S651.	3.7	2
157	Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?. Journal of Hepatology, 2015, 63, 83-92.	3.7	101
158	Prevention of Post-transplant HBV. Current Hepatology Reports, 2015, 14, 153-163.	0.9	0
159	Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. American Journal of Transplantation, 2015, 15, 1267-1282.	4.7	58
160	The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable. Journal of Hepatology, 2015, 63, 1041-1042.	3.7	11
161	Patients with acute liver failure listed for superurgent liver transplantation in France: Reevaluation of the clichyàvillejuif criteria. Liver Transplantation, 2015, 21, 512-523.	2.4	49
162	Universal Hepatitis B Virus Screening in Patients Receiving Immunosuppressive Therapy: A Small Step for the Oncologists, a Major Advance for Prevention of Hepatitis B Virus Reactivation. Clinical Gastroenterology and Hepatology, 2015, 13, 976-978.	4.4	3

#	ARTICLE	IF	CITATIONS
163	Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 604-612.	0.6	8
164	From immunosuppression to tolerance. <i>Journal of Hepatology</i> , 2015, 62, S170-S185.	3.7	133
165	Transplantation for Hepatitis A and B. , 2015, , 105-119.		0
166	Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. <i>Aids</i> , 2015, 29, 53-58.	2.2	28
167	Management of post transplant hepatitis C in the direct antiviral agents era. <i>Hepatology International</i> , 2015, 9, 192-201.	4.2	7
168	P1107 : Unconsidered misuse of acetaminophen is one of the causal cofactors of acute liver failure in adults with severe dengue fever. <i>Journal of Hepatology</i> , 2015, 62, S765.	3.7	0
169	Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. <i>Radiology</i> , 2015, 277, 443-453.	7.3	17
170	The effect of new HCV drugs on liver transplantation outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 559-560.	17.8	1
171	P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study. <i>Journal of Hepatology</i> , 2015, 62, S635-S636.	3.7	5
172	Extreme Bradycardia After First Doses of Sofosbuvir and Daclatasvir in Patients Receiving Amiodarone: 2 Cases Including a Rechallenge. <i>Gastroenterology</i> , 2015, 149, 1378-1380.e1.	1.3	71
173	Alcoholic liver disease: Clinical and translational research. <i>Experimental and Molecular Pathology</i> , 2015, 99, 596-610.	2.1	36
174	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	1.3	317
175	Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. <i>Liver International</i> , 2015, 35, 44-50.	3.9	22
176	Hepatitis E infection in patients with severe acute alcoholic hepatitis. <i>Liver International</i> , 2015, 35, 870-875.	3.9	22
177	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. <i>Hepatology International</i> , 2014, 8, 453-471.	4.2	861
178	Long-term results of combined liver-kidney transplantation for Primary Hyperoxaluria Type 1: The French experience. <i>Liver Transplantation</i> , 2014, 20, n/a-n/a.	2.4	30
179	Optimal Management of HCV Transplant Patients. <i>Current Hepatology Reports</i> , 2014, 13, 304-313.	0.9	0
180	Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors. <i>Oncolmmunology</i> , 2014, 3, e28782.	4.6	2

#	ARTICLE	IF	CITATIONS
181	Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?. <i>Aids</i> , 2014, 28, 1379-1391.	2.2	25
182	Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2014, 146, 138-146.e5.	1.3	99
183	Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. <i>Journal of Hepatology</i> , 2014, 60, 78-86.	3.7	182
184	Journal of Hepatology, an international top rank journal. <i>Journal of Hepatology</i> , 2014, 60, 3.	3.7	10
185	P1319 ONCE-DAILY SIMPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL. <i>Journal of Hepatology</i> , 2014, 60, S535.	3.7	24
186	P334 AN INFLAMMATORY EXTRACELLULAR MATRIX IS A MOLECULAR TARGET OF THE ROS SCAVENGER HIP/PAP. <i>Journal of Hepatology</i> , 2014, 60, S178.	3.7	0
187	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.3	232
188	Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. <i>Journal of Hepatology</i> , 2014, 60, 570-578.	3.7	129
189	Long term results of liver transplantation for Wilson's disease: Experience in France. <i>Journal of Hepatology</i> , 2014, 60, 579-589.	3.7	103
190	Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients. <i>Intervirology</i> , 2014, 57, 196-201.	2.8	21
191	Expansion of CMV-Mediated NKG2C+ NK Cells Associates with the Development of Specific De Novo Malignancies in Liver-Transplanted Patients. <i>Journal of Immunology</i> , 2014, 192, 503-511.	0.8	28
192	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	3.7	741
193	Liver transplantation for alcoholic hepatitis. Current situation and future. <i>Hepatology International</i> , 2014, 8, 481-485.	4.2	3
194	Management of HCV transplant patients with triple therapy. <i>Liver International</i> , 2014, 34, 46-52.	3.9	26
195	P1111 ANRS HC15 NRF1: LONG-TERM MAINTENANCE THERAPY WITH A COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON IN CHRONIC HEPATITIS C. RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED TRIAL. <i>Journal of Hepatology</i> , 2014, 60, S448-S449.	3.7	0
196	P1237 ANTI-HEPATITIS C (HCV) TRIPLE THERAPY WITH PROTEASE INHIBITORS IN HIV/HCV CO-INFECTED PATIENTS AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2014, 60, S501.	3.7	1
197	Should we screen blood products for hepatitis E virus RNA ?. <i>Lancet, The</i> , 2014, 383, 218.	13.7	50
198	Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: A French experience on 250 patients over 15 years (the Orfèvre study). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 292-299.	1.5	5

#	ARTICLE	IF	CITATIONS
199	P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY. <i>Journal of Hepatology</i> , 2014, 60, S499.	3.7	20
200	P455 BACTERIAL ENDOCARDITIS IN PATIENTS WITH CIRRHOSIS: A MULTICENTER RETROSPECTIVE STUDY OF 78 CASES. <i>Journal of Hepatology</i> , 2014, 60, S220-S221.	3.7	0
201	P910 IMPACT OF ANEMIA IN VIRAL RESPONSE DURING TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2014, 60, S378.	3.7	0
202	O49 SEPTIN 9 BINDS PtdIns4P AND REGULATES LIPID DROPLETS DISTRIBUTION IN HCV INFECTED CELLS. <i>Journal of Hepatology</i> , 2014, 60, S20.	3.7	0
203	P508 VALIDATION OF THE CLIF-CONSORTIUM (CLIF-C) SCORE TO PREDICT MORTALITY OF PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) IN AN EXTERNAL COHORT AND FOR SEQUENTIAL MEASUREMENTS. <i>Journal of Hepatology</i> , 2014, 60, S239.	3.7	3
204	P694 HEPATITIS E INFECTION IN PATIENTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS. <i>Journal of Hepatology</i> , 2014, 60, S300.	3.7	0
205	Five exciting years at the <i>Journal of Hepatology</i> – An open road to the future. <i>Journal of Hepatology</i> , 2014, 61, 1193-1195.	3.7	0
206	Hepatitis C and Liver Transplantation in the HIV Co-infected Patients. , 2014, , 65-76.		0
207	The international vision of the <i>Journal of Hepatology</i> . <i>Journal of Hepatology</i> , 2013, 58, 3.	3.7	4
208	1070 DISCRIMINATING CIRRHOSIS AND HEPATOCELLULAR CARCINOMA BY IN SITU CHEMICAL ANALYSIS USING INFRARED MICROSPECTROSCOPY. <i>Journal of Hepatology</i> , 2013, 58, S438-S439.	3.7	0
209	The positive financial impact of using an Intensive Care Information System in a tertiary Intensive Care Unit. <i>International Journal of Medical Informatics</i> , 2013, 82, 177-184.	3.3	10
210	60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPLIC). <i>Journal of Hepatology</i> , 2013, 58, S27.	3.7	30
211	Albumin Dialysis With a Noncell Artificial Liver Support Device in Patients With Acute Liver Failure. <i>Annals of Internal Medicine</i> , 2013, 159, 522.	3.9	231
212	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPLIC) – NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	3.7	407
213	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach. <i>Liver Transplantation</i> , 2013, 19, 69-77.	2.4	18
214	Acute liver failure: Current trends. <i>Journal of Hepatology</i> , 2013, 59, 6-8.	3.7	26
215	170 IMPACT OF ADJUVANT CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA BEYOND MILAN ON HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2013, 58, S75-S76.	3.7	0
216	1042 HEPATOCELLULAR CARCINOMA REPLICATING HEPATITIS B VIRUS HAVE TRANSCRIPTOMIC, HISTOLOGICAL AND CLINICAL CHARACTERISTICS. <i>Journal of Hepatology</i> , 2013, 58, S428.	3.7	0

#	ARTICLE	IF	CITATIONS
217	HCV core-mediated activation of latent TGF- β 2 via thrombospondin drives the crosstalk between hepatocytes and stromal environment. <i>Journal of Hepatology</i> , 2013, 59, 1160-1168.	3.7	53
218	Treatment of Patients with HBV-related Decompensated Cirrhosis and Liver Transplanted Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 451-473.	2.1	14
219	184 PREDICTIVE FACTORS OF SURVIVAL AND PROGNOSTIC SCORE VALIDATION IN LIVER RETRANSPLANTATION FOR SEVERE HEPATITIS C RECURRENCE: THE IMPORTANCE OF HCV THERAPY BEFORE AND AFTER RETRANSPLANTATION. <i>Journal of Hepatology</i> , 2013, 58, S81.	3.7	0
220	997 FULMINANT HEPATITIS LISTED FOR EMERGENCY LIVER TRANSPLANTATION IN FRANCE – EPIDEMIOLOGY AND OUTCOME. <i>Journal of Hepatology</i> , 2013, 58, S411.	3.7	0
221	991 ACUTE LIVER FAILURE IN HIV INFECTED PATIENTS: A SINGLE CENTER EXPERIENCE. <i>Journal of Hepatology</i> , 2013, 58, S409.	3.7	4
222	140 IMPACT OF SARCOPENIA ON MORTALITY AFTER LIVER TRANSPLANTATION IN HIV INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S63.	3.7	4
223	1422 END OF TREATMENT RESPONSE AFTER PROTEASE INHIBITOR (PI)- BASED THERAPY FOR HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A MULTICENTRIC EUROPEAN EXPERIENCE. <i>Journal of Hepatology</i> , 2013, 58, S572-S573.	3.7	10
224	Human Herpesvirus 8 (HHV8) Transmission and Related Morbidity in Organ Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 207-213.	4.7	53
225	Current management and perspectives for HCV recurrence after liver transplantation. <i>Liver International</i> , 2013, 33, 56-62.	3.9	50
226	Epstein-Barr Virus Infection and Altered Control of Apoptotic Pathways in Posttransplant Lymphoproliferative Disorders. <i>Pathobiology</i> , 2013, 80, 53-59.	3.8	16
227	HRas Signal Transduction Promotes Hepatitis C Virus Cell Entry by Triggering Assembly of the Host Tetraspanin Receptor Complex. <i>Cell Host and Microbe</i> , 2013, 13, 302-313.	11.0	141
228	Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 788-791.	4.2	3
229	Liver transplantation in the human immunodeficiency virus-hepatitis C virus coinfecting patient: Time to sum up. <i>Hepatology</i> , 2013, 57, 409-411.	7.3	3
230	Immunoproteomic Analysis of Potentially Severe Non-Graft-Versus-Host Disease Hepatitis After Allogeneic Bone Marrow Transplantation. <i>Hepatology</i> , 2013, 57, 689-699.	7.3	9
231	Cirrhotic patients in the ICU. <i>Current Opinion in Critical Care</i> , 2013, 19, 154-160.	3.2	70
232	Persistence of Yellow Fever Vaccine-Induced Antibodies After Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 2458-2461.	4.7	37
233	Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. <i>Clinical Transplantation</i> , 2013, 27, E454-61.	1.6	84
234	Reversibility of Acquired Amyloid Polyneuropathy After Liver Retransplantation. <i>American Journal of Transplantation</i> , 2013, 13, 2734-2738.	4.7	22

#	ARTICLE	IF	CITATIONS
235	Acute Hepatitis With Periportal Confluent Necrosis Associated With Human Herpesvirus 6 Infection in Liver Transplant Patients. <i>American Journal of Clinical Pathology</i> , 2013, 140, 403-409.	0.7	27
236	Histologic Findings Predictive of a Diagnosis of De novo Autoimmune Hepatitis After Liver Transplantation in Adults. <i>Transplantation</i> , 2013, 96, 670-678.	1.0	36
237	Posttransplantation Hepatitis E. <i>Transplantation</i> , 2013, 96, e4-e6.	1.0	43
238	Postliver Transplantation Pulmonary Complications. <i>Transplantation</i> , 2013, 95, e43-e44.	1.0	0
239	Lengthy Follow-up After Liver Transplantation for Nodular Regenerative Hyperplasia in Human Immunodeficiency Virus-Infected Patients. <i>Transplantation</i> , 2013, 96, e79-e81.	1.0	4
240	Liver Transplantation in Delta Virus Infection. <i>Seminars in Liver Disease</i> , 2012, 32, 245-255.	3.6	49
241	Recombination of hepatitis B virus DNA in patients with HIV. <i>Gut</i> , 2012, 61, 1197-1208.	12.1	6
242	Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases: Figure 1. <i>Gut</i> , 2012, 61, 1098-1100.	12.1	3
243	Pulmonary Complications After Elective Liver Transplantation—Incidence, Risk Factors, and Outcome. <i>Transplantation</i> , 2012, 94, 532-538.	1.0	71
244	Resection or Transplantation for Early Hepatocellular Carcinoma in a Cirrhotic Liver. <i>Annals of Surgery</i> , 2012, 256, 883-891.	4.2	76
245	8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS) Tj ETQq1 1 0.7843 14 rgB51 Overlo		
246	47 EFFICACY AND SAFETY OF PROTEASE INHIBITORS FOR SEVERE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A FIRST MULTICENTRIC EXPERIENCE. <i>Journal of Hepatology</i> , 2012, 56, S21.	3.7	29
247	190 DE NOVO AUTO-IMMUNE HEPATITIS AND HCV RECURRENCE AFTER LIVER TRANSPLANTATION: A CHALLENGING DIAGNOSIS AND POOR PROGNOSIS. <i>Journal of Hepatology</i> , 2012, 56, S82.	3.7	0
248	209 SYSTEMATIC CT-SCAN ON POST-OPERATIVE DAY 7 AFTER LIVER TRANSPLANTATION DECREASES THE RATE OF RETRANSPLANTATION FOR ARTERIAL COMPLICATIONS. <i>Journal of Hepatology</i> , 2012, 56, S89.	3.7	0
249	219 PROSPECTIVE ASSESSMENT OF LIVER FIBROSIS AFTER LIVER TRANSPLANTATION IN HIV/HCV COINFECTED PATIENTS: A USEFUL TOOL ASSESSING SEVERE FIBROSIS ON THE LIVER GRAFT. <i>Journal of Hepatology</i> , 2012, 56, S93.	3.7	1
250	221 20-YEAR PROTOCOL LIVER BIOPSIES: INVASIVE BUT USEFUL FOR THE MANAGEMENT OF LIVER RECIPIENTS. <i>Journal of Hepatology</i> , 2012, 56, S93-S94.	3.7	1
251	255 GAMMA SMOOTH MUSCLE ACTIN: AN EPITHELIAL MESENCHYMAL TRANSITION MARKER IN HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2012, 56, S107.	3.7	0
252	688 RISK FACTORS FOR HEPATOCELLULAR CARCINOMA OR LIVER FAILURE IN CAUCASIANS PATIENTS WITH NON-VIRAL CIRRHOSIS: THE IMPORTANCE OF PAST OVERWEIGHT. <i>Journal of Hepatology</i> , 2012, 56, S273.	3.7	0

#	ARTICLE	IF	CITATIONS
253	840 SEPTIN 9 REGULATES LIPID DROPLETS ACCUMULATION AND HEPATITIS C VIRUS REPLICATION IN A SUMO1 DEPENDENT PROCESS. <i>Journal of Hepatology</i> , 2012, 56, S328.	3.7	0
254	937 AUTOIMMUNE-LIKE HEPATITIS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION: A NEW ENTITY CHARACTERISED BY USING A PROTEOMIC APPROACH. <i>Journal of Hepatology</i> , 2012, 56, S366.	3.7	0
255	976 CENTRILOBULAR CHANGES ARE KEY HISTOLOGICAL FINDINGS FOR SEGREGATING CASES OF DE NOVO AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2012, 56, S381-S382.	3.7	1
256	Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha. <i>Transplant International</i> , 2012, 25, 941-947.	1.6	9
257	1031 PROGNOSTIC FACTORS AT TEN YEARS AFTER LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2012, 56, S403.	3.7	0
258	Iodide Transporter NIS Regulates Cancer Cell Motility and Invasiveness by Interacting with the Rho Guanine Nucleotide Exchange Factor LARG. <i>Cancer Research</i> , 2012, 72, 5505-5515.	0.9	37
259	Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5728-5734.	3.2	51
260	Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an Intensive Care Unit. <i>Journal of Hepatology</i> , 2012, 56, 95-102.	3.7	172
261	The Journal of Hepatology: An international journal in a new era. <i>Journal of Hepatology</i> , 2012, 56, 4.	3.7	7
262	Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. <i>Journal of Hepatology</i> , 2012, 56, 840-847.	3.7	48
263	Reply to: "Patients with cirrhosis admitted to an Intensive Care Unit". <i>Journal of Hepatology</i> , 2012, 57, 231-232.	3.7	2
264	Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFN±-2a plus ribavirin. <i>Journal of Hepatology</i> , 2012, 57, 564-571.	3.7	27
265	Combined Prophylaxis Might Still Be Better Than Monoprophylaxis With Entecavir Following Liver Transplantation for Hepatitis B. <i>Gastroenterology</i> , 2012, 142, e34.	1.3	4
266	A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. <i>Journal of Transplantation</i> , 2012, 2012, 1-9.	0.5	29
267	Hepatitis C virus treatment pre- and post-liver transplantation. <i>Liver International</i> , 2012, 32, 120-128.	3.9	62
268	1313 AUTOANTIGEN IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS IN PATIENTS WITH A NEW TYPE OF AUTOIMMUNE-LIKE HEPATITIS OCCURRING AFTER BONE MARROW TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S517-S518.	3.7	0
269	Epidemiology of liver failure. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 610-617.	1.5	47
270	Early Liver Transplantation for Severe Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2011, 365, 1790-1800.	27.0	792

#	ARTICLE	IF	CITATIONS
271	Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 242-248.	4.4	28
272	Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. <i>Journal of Hepatology</i> , 2011, 54, 481-488.	3.7	76
273	First year and beyond. <i>Journal of Hepatology</i> , 2011, 54, 3.	3.7	7
274	76S HCV CORE PROTEIN MODULATES TGF- β RESPONSES IN AN AUTOCRINE AND PARACRINE MANNER, A NOVEL PARADIGM FOR THE INTERPLAY BETWEEN HOST- AND VIRAL-RELATED CARCINOGENETIC SIGNALS. <i>Journal of Hepatology</i> , 2011, 54, S308.	3.7	0
275	Liver transplant outcomes in HIV-infected patients. <i>Aids</i> , 2011, 25, 1675-1676.	2.2	8
276	Noninvasive ICG clearance: a useful tool for the management of hepatic artery thrombosis following liver transplantation. <i>Clinical Transplantation</i> , 2011, 25, 297-301.	1.6	30
277	The difficulties of managing severe hepatitis B virus reactivation. <i>Liver International</i> , 2011, 31, 104-110.	3.9	55
278	Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. <i>Liver International</i> , 2011, 31, 676-684.	3.9	43
279	Short- and Long-term Donor Morbidity in Right Lobe Living Donor Liver Transplantation: 91 Consecutive Cases in a European Center. <i>American Journal of Transplantation</i> , 2011, 11, 101-110.	4.7	87
280	Fibrosing Cholestatic Hepatitis in HIV/HCV Co-Infected Transplant Patients – Usefulness of Early Markers After Liver Transplantation. <i>American Journal of Transplantation</i> , 2011, 11, 1686-1695.	4.7	55
281	Respiratory impact of paracentesis in cirrhotic patients with acute lung injury. <i>Journal of Critical Care</i> , 2011, 26, 257-261.	2.2	21
282	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial. <i>Liver Transplantation</i> , 2011, 17, 167-177.	2.4	51
283	Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 798-808.	2.4	39
284	Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no. <i>Liver Transplantation</i> , 2011, 17, 488-491.	2.4	6
285	Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system. <i>Liver Transplantation</i> , 2011, 17, 1137-1151.	2.4	68
286	Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011, 17, S6-S13.	2.4	53
287	Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection. <i>Hepatology</i> , 2011, 53, 475-482.	7.3	45
288	Human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers. <i>Hepatology</i> , 2011, 53, 618-627.	7.3	37

#	ARTICLE	IF	CITATIONS
289	Reply:. Hepatology, 2011, 53, 2138-2139.	7.3	1
290	Autoimmune acute liver failure. Hepatology, 2011, 54, 372-372.	7.3	8
291	Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients. Transplantation, 2010, 89, 1504-1510.	1.0	50
292	EFFICACY AND LONG-TERM OUTCOME OF AMPHOTERICIN B LIPID COMPLEX (ABLC) PROPHYLAXIS IN HIGH RISK LIVER TRANSPLANT RECIPIENTS IN THE CURRENT PRACTICE. Transplantation, 2010, 90, 116.	1.0	0
293	Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor. American Journal of Transplantation, 2010, 10, 129-137.	4.7	213
294	Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transplantation, 2010, 16, 885-894.	2.4	28
295	Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. Liver Transplantation, 2010, 16, 1136-1146.	2.4	28
296	Hepatitis C virus: Up to the minute. Liver Transplantation, 2010, 16, S26-S35.	2.4	14
297	Successful Long-term Outcome of ABO-incompatible Liver Transplantation Using Antigen-specific Immunoabsorption Columns. Therapeutic Apheresis and Dialysis, 2010, 14, 116-123.	0.9	16
298	Factors associated with nutritional status in liver transplant patients who survived the first year after transplantation. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 391-396.	2.8	22
299	Viral load predicts HBV recurrence after liver transplant. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 657-658.	17.8	1
300	RISK ASSESSMENT OF LIVER DONATION FOR PATIENTS WITH FAMILIAL AMYLOID POLYNEUROPATHY IN DOMINO LIVER TRANSPLANTATION: 100 CASES FROM A SINGLE CENTER. Transplantation, 2010, 90, 449.	1.0	0
301	1095 DEMONSTRATION OF AN HEPATOCYTE CANALICULAR LOCALIZATION OF CYP2D6, THE TARGET OF LIVER KIDNEY MICROSOME TYPE 1 AUTOANTIBODIES, MARKERS OF TYPE 2 AUTOIMMUNE HEPATITIS. Journal of Hepatology, 2010, 52, S423.	3.7	0
302	ATP release after partial hepatectomy regulates liver regeneration in the rat. Journal of Hepatology, 2010, 52, 54-62.	3.7	91
303	Focus. Journal of Hepatology, 2010, 52, 3-4.	3.7	0
304	Are viral or host factors predictive of response to interferon-ribavirin in transplant patients with hepatitis C?. Journal of Hepatology, 2010, 52, 630-632.	3.7	2
305	Prognosis indicator in acute liver failure: Is there a place for cell death markers?. Journal of Hepatology, 2010, 53, 593-595.	3.7	15
306	29 EARLY TRANSPLANTATION IMPROVES SURVIVAL OF NON-RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A CHALLENGE TO THE 6 MONTH RULE OF ABSTINENCE. Journal of Hepatology, 2010, 52, S13.	3.7	9

#	ARTICLE	IF	CITATIONS
307	30 ACUTE LIVER FAILURE: CURRENT EUROPEAN PERSPECTIVE. <i>Journal of Hepatology</i> , 2010, 52, S13-S14.	3.7	5
308	41 THE SODIUM IODIDE SYMPORTER ENHANCES CELL MIGRATION AND INVASION. <i>Journal of Hepatology</i> , 2010, 52, S18.	3.7	1
309	464 CHARACTERISTICS AND PROGNOSIS OF FIBROSING CHOLESTATIC HEPATITIS AFTER LIVER TRANSPLANTATION IN A LARGE COHORT OF HIV/HCV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S188.	3.7	0
310	465 LONG TERM RESULTS OF LIVER TRANSPLANTATION FOR WILSON'S DISEASE (WD): THE FRENCH EXPERIENCE. <i>Journal of Hepatology</i> , 2010, 52, S188-S189.	3.7	0
311	493 RESULTS OF LIVER RETRANSPLANTATION IN A MONOCENTRIC COHORT OF HCV INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S199.	3.7	0
312	495 ARE LIVER TRANSPLANT HIV-1 INFECTED PATIENTS AT RISK TO DEVELOP HIV-1 DRUG RESISTANCE?. <i>Journal of Hepatology</i> , 2010, 52, S199-S200.	3.7	0
313	823 INDETERMINATE CAUSES OF ACUTE LIVER FAILURE: INCIDENCE AND PREDICTIVE FACTORS OF SPONTANEOUS SURVIVAL AND AFTER LIVER TRANSPLANTATION (LT). <i>Journal of Hepatology</i> , 2010, 52, S321.	3.7	1
314	866 IDENTIFICATION OF NOVEL CELLULAR TARGETS IN HUMAN INTRAHEPATIC CHOLANGIOCARCINOMA USING LASER MICRODISSECTION AND AMT-TAG PROTEOMICS. <i>Journal of Hepatology</i> , 2010, 52, S337.	3.7	0
315	929 ANTI-OXIDANT CURATIVE EFFECT OF A MANUFACTURED HIP/PAP PROTEIN AGAINST FULMINANT HEPATITIS. <i>Journal of Hepatology</i> , 2010, 52, S360.	3.7	0
316	1041 HCV CORE PROTEIN INDUCES INTRAHEPATIC TGF-BETA ACTIVATION IN TRANSGENIC MICE. <i>Journal of Hepatology</i> , 2010, 52, S403.	3.7	0
317	Liver Cancer-Derived Hepatitis C Virus Core Proteins Shift TGF-Beta Responses from Tumor Suppression to Epithelial-Mesenchymal Transition. <i>PLoS ONE</i> , 2009, 4, e4355.	2.5	110
318	Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfecting patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. <i>Aids</i> , 2009, 23, 1069-1076.	2.2	47
319	Steroid use in HCV-infected liver transplant recipients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 198-200.	17.8	5
320	Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The ReSpECT™ Study. <i>American Journal of Transplantation</i> , 2009, 9, 327-336.	4.7	250
321	Plasma disappearance rate of indocyanine green: A tool to evaluate early graft outcome after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1358-1364.	2.4	70
322	Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1336-1342.	2.4	5
323	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). <i>Hepatology International</i> , 2009, 3, 269-282.	4.2	709
324	MELD-Na as a prognostic score for cirrhotic patients: Hyponatremia and ascites are back in the game. <i>Journal of Hepatology</i> , 2009, 50, 836-838.	3.7	35

#	ARTICLE	IF	CITATIONS
325	Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results. <i>Journal of Hepatology</i> , 2009, 50, 652-654.	3.7	16
326	Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV/HCV coinfecting patients (ANRS-HC08 "THEVICA" trial). <i>Journal of Hepatology</i> , 2009, 51, 1000-1009.	3.7	11
327	Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. <i>Digestive and Liver Disease</i> , 2009, 41, 350-356.	0.9	76
328	220 PREDICTIVE FACTORS OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH FULMINANT AND SUBFULMINANT HEPATIC FAILURE: RESULTS FROM A RANDOMIZED CONTROLLED MULTICENTER TRIAL. <i>Journal of Hepatology</i> , 2009, 50, S89-S90.	3.7	18
329	221 OUTCOME OF CIRRHOTIC PATIENTS ADMITTED TO THE LIVER ICU AND PREDICTIVE FACTORS OF MORTALITY: RESULTS OF A RECENT COHORT OF 308 PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S90.	3.7	1
330	237 HCV CORE-DEPENDENT DECREASE OF SMAD3 ACTIVATION PROMOTES TGF- β 2-INDUCED EPITHELIAL MESENCHYMAL TRANSITION. <i>Journal of Hepatology</i> , 2009, 50, S96.	3.7	0
331	398 HUMORAL NEUTRALIZING RESPONSE TO HCV DURING HIV COINFECTION AND LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2009, 50, S151.	3.7	0
332	443 PROGNOSIS OF SEVERE RECURRENCE OF HCV INFECTION AFTER LIVER TRANSPLANTATION IN A LARGE COHORT OF HIV INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S168.	3.7	0
333	459 ANALYSE OF PREDICTIVE FACTORS OF MORTALITY OF HIV/HCV INFECTED PATIENTS ON THE WAITING LIST OF LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2009, 50, S173.	3.7	0
334	846 ATP RELEASE AFTER PARTIAL HEPATECTOMY REGULATES LIVER REGENERATION. <i>Journal of Hepatology</i> , 2009, 50, S308.	3.7	1
335	Survival and recurrence of hepatitis C after liver transplantation in patients coinfecting with human immunodeficiency virus and hepatitis C virus. <i>Hepatology</i> , 2008, 47, 407-417.	7.3	178
336	A new indication for liver transplantation: Nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. <i>Liver Transplantation</i> , 2008, 14, 1194-1198.	2.4	46
337	Chickenpox-associated fulminant hepatitis that led to liver transplantation in a 63-year-old woman. <i>Liver Transplantation</i> , 2008, 14, 1309-1312.	2.4	26
338	Etiology and prognosis of fulminant hepatitis in adults. <i>Liver Transplantation</i> , 2008, 14, S67-S79.	2.4	157
339	Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. <i>Liver Transplantation</i> , 2008, 14, 1766-1777.	2.4	129
340	Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. <i>Hepatology</i> , 2008, 47, 937-948.	7.3	34
341	Liver transplantation in viral hepatitis: Prevention of recurrence. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1153-1169.	2.4	16
342	Hepatocellular Carcinoma Is Associated With an Increased Risk of Hepatitis B Virus Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2008, 134, 1890-1899.	1.3	155

#	ARTICLE	IF	CITATIONS
343	Are HIV-infected patients candidates for liver transplantation?. <i>Journal of Hepatology</i> , 2008, 48, 697-707.	3.7	44
344	Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation?. <i>Journal of Hepatology</i> , 2008, 49, 498-501.	3.7	1
345	Internal Radiotherapy of Liver Cancer with Rat Hepatocarcinoma-Intestine-Pancreas Gene as a Liver Tumor-Specific Promoter. <i>Human Gene Therapy</i> , 2008, 19, 915-926.	2.7	28
346	71 RISK OF HBV TRANSMISSION IN RECIPIENTS OF LIVER GRAFT FROM HBC ANTIBODY POSITIVE DONORS USING HBIG MONO-PROPHYLAXIS. <i>Journal of Hepatology</i> , 2008, 48, S31.	3.7	1
347	170 VASOPRESSIN-BASED REFLEX REGULATING PORTAL PRESSURE AND BILE HOMEOSTASIS AFTER PARTIAL HEPATECTOMY IN RATS AND HUMANS. <i>Journal of Hepatology</i> , 2008, 48, S73.	3.7	1
348	191 EVOLUTION AFTER LISTING AND RESULTS OF LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN HIV/HCV AND HIV/HBV COINFECTED PATIENTS. <i>Journal of Hepatology</i> , 2008, 48, S80-S81.	3.7	0
349	233 EFFECT OF ANTIVIRAL TREATMENT, RETREATMENT, AND STAGE OF FIBROSIS ON PROGRESSION OF LIVER FIBROSIS, AND OUTCOME AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2008, 48, S95-S96.	3.7	0
350	423 HCV CORE TUMOR VARIANTS SHIFT TGF-BETA RESPONSES FROM TUMOR SUPPRESSION TO ONCOGENESIS IN PRIMARY HUMAN AND MOUSE HEPATOCYTES. <i>Journal of Hepatology</i> , 2008, 48, S163.	3.7	0
351	542 INTERNAL RADIOTHERAPY OF LIVER CANCER USING RAT HEPATOCARCINOMA-INTESTINE-PANCREAS GENE AS A LIVER TUMOR-SPECIFIC PROMOTER. <i>Journal of Hepatology</i> , 2008, 48, S203-S204.	3.7	0
352	860 HNRNP A2/B1 AS ANTINUCLEAR ANTIBODIES TARGET: EPITOPE MAPPING AND DIFFERENTIAL REACTIVITY IN AUTOIMMUNE HEPATITIS AND CONNECTIVE TISSUE DISEASES. <i>Journal of Hepatology</i> , 2008, 48, S323.	3.7	0
353	999 LOW-DOSE PEGINTERFERON ALFA-2A (40KD) (PEGASYSA®) TO TREAT HEPATITIS C-INFECTED, END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: FINAL STUDY RESULTS. <i>Journal of Hepatology</i> , 2008, 48, S374.	3.7	2
354	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 719-727.	0.7	41
355	Pneumocystis pneumonia: an opportunistic infection occurring in patients with severe alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 26-28.	1.6	18
356	New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation?. <i>Transplant Immunology</i> , 2007, 17, 98-107.	1.2	12
357	Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success. <i>Journal of Hepatology</i> , 2007, 46, 988-991.	3.7	15
358	[36] EVOLUTION OF AETIOLOGY AND OUTCOME IN THE LAST 20 YEARS IN 500 PATIENTS WITH ACUTE LIVER FAILURE. FACTORS PREDICTIVE OF SURVIVAL AND OF NEUROLOGICAL SEQUELLAE. <i>Journal of Hepatology</i> , 2007, 46, S17.	3.7	1
359	[139] POST-ASPIRIN REYE'S SYNDROME IN YOUNG ADULTS: FREQUENT AGGRAVATION OF ENCEPHALOPATHY BY NEUROTROPIC DRUGS AND SPONTANEOUS RECOVERY. <i>Journal of Hepatology</i> , 2007, 46, S63.	3.7	3
360	[154] SURVIVAL ANALYSIS OF HIV INFECTED PATIENTS REFERRED TO A LIVER TRANSPLANT UNIT. <i>Journal of Hepatology</i> , 2007, 46, S68.	3.7	0

#	ARTICLE	IF	CITATIONS
361	[175] SPECIFIC ANTI-HCV IMMUNE RESPONSES AFTER LIVER TRANSPLANTATION IN HIV/HCV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2007, 46, S75.	3.7	0
362	[628] USE OF LOW-DOSE PEGINTERFERON a-2a (40 kD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: INTERIM RESULTS FROM A RANDOMISED STUDY. <i>Journal of Hepatology</i> , 2007, 46, S237-S238.	3.7	2
363	Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study. <i>Clinical Pharmacokinetics</i> , 2007, 46, 941-952.	3.5	56
364	Sodium Iodide Symporter Is Expressed at the Preneoplastic Stages of Liver Carcinogenesis and in Human Cholangiocarcinoma. <i>Gastroenterology</i> , 2007, 132, 1495-1503.	1.3	24
365	Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. <i>Hepatology</i> , 2007, 46, 1704-1712.	7.3	44
366	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	2.4	239
367	Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. <i>Liver Transplantation</i> , 2007, 13, 996-1003.	2.4	229
368	New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: What will be their impact on the prophylaxis of HBV infection?. <i>Liver Transplantation</i> , 2007, 13, 1084-1087.	2.4	4
369	Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1004-1010.	2.4	46
370	Domino liver transplantation from familial amyloidotic polyneuropathy donors: how close is the damocles sword to the recipient?. <i>Transplant International</i> , 2007, 20, 921-923.	1.6	12
371	Risk factors for hepatitis C recurrence after liver transplantation. <i>Journal of Viral Hepatitis</i> , 2007, 14, 89-96.	2.0	89
372	Identification by Proteomic Tool of Atypical Anti-Liver/Kidney Microsome Autoantibodies Targets in de Novo Autoimmune Hepatitis after Liver Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 345-357.	3.8	27
373	A Decision Analysis Model Identifies the Interval of Efficacy for Transarterial Chemoembolization (TACE) in Cirrhotic Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1328-1332.	1.7	23
374	2 Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation. <i>Journal of Hepatology</i> , 2006, 44, S3.	3.7	2
375	139 Etiology, outcome and early causes of death in 427 patients with acute liver failure (ALF): A 20 year single-center experience. <i>Journal of Hepatology</i> , 2006, 44, S61.	3.7	3
376	161 Albumin dialysis using the MARS® system in the treatment of patients with end-stage liver disease and renal failure. <i>Journal of Hepatology</i> , 2006, 44, S68.	3.7	0
377	245 Comparative proteomic analysis of hepatocellular carcinomas on non-fibrotic liver and hepatocellular adenomas. <i>Journal of Hepatology</i> , 2006, 44, S98.	3.7	0
378	629 Identification of new autoantigens on liver plasma membranes in type 1 autoimmune hepatitis by proteome analysis. <i>Journal of Hepatology</i> , 2006, 44, S233-S234.	3.7	0

#	ARTICLE	IF	CITATIONS
379	Clinical and Therapeutic Implications of Hepatitis C Virus Compartmentalization. <i>Gastroenterology</i> , 2006, 131, 76-84.	1.3	86
380	Cadaveric full-size liver transplantation and the graft alternatives in adults: A comparative study from a single centre. <i>Journal of Hepatology</i> , 2006, 44, 118-125.	3.7	22
381	Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. <i>Journal of Hepatology</i> , 2006, 45, 355-360.	3.7	96
382	Liver Retransplantation: A Model for Determining Long-Term Survival. <i>Transplantation</i> , 2006, 81, 1016-1021.	1.0	48
383	Aspects of hepatitis C virus infection relating to liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 313-320.	1.6	13
384	Liver transplantation in HIV-infected patients. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 608-612.	1.6	2
385	Medical community preferences concerning adult living related donor liver transplantation. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 183-187.	0.9	4
386	Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. <i>Liver Transplantation</i> , 2006, 12, 1640-1648.	2.4	129
387	The difficulty in timing for liver transplantation in cirrhotic patients coinfecting with HIV: In search for a prognosis score. <i>Liver Transplantation</i> , 2006, 12, 699-701.	2.4	11
388	12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. <i>Liver Transplantation</i> , 2006, 12, 1464-1472.	2.4	92
389	Liver transplantation for fulminant hepatitis related to nevirapine therapy. <i>Liver Transplantation</i> , 2006, 12, 1880-1882.	2.4	22
390	Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 4911.	3.3	12
391	Treatment of hepatitis δ and C after liver transplantation. Part 1, hepatitis δ . <i>Transplant International</i> , 2005, 17, 746-58.	1.6	9
392	Treatment of hepatitis δ and C after liver transplantation. Part 2, hepatitis δ . <i>Transplant International</i> , 2005, , .	1.6	0
393	Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis?. <i>Clinical Transplantation</i> , 2005, 19, 591-599.	1.6	23
394	Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach. <i>Hepatology</i> , 2005, 41, 436-438.	7.3	14
395	Male cell microchimerism in normal and diseased female livers from fetal life to adulthood. <i>Hepatology</i> , 2005, 42, 35-43.	7.3	64
396	Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. <i>Liver Transplantation</i> , 2005, 11, 716-732.	2.4	168

#	ARTICLE	IF	CITATIONS
397	Herpes simplex virus-associated acute liver failure: A difficult diagnosis with a poor prognosis. Liver Transplantation, 2005, 11, 1550-1555.	2.4	111
398	Compartmentalization of Hepatitis C Virus Genotypes between Plasma and Peripheral Blood Mononuclear Cells. Journal of Virology, 2005, 79, 6349-6357.	3.4	132
399	Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV/HCV co-infected patients. Journal of Hepatology, 2005, 42, 341-349.	3.7	49
400	The questionable role of immunization against hepatitis B in HBV infected liver transplant patients. Journal of Hepatology, 2005, 43, 203-206.	3.7	11
401	Transplantation for Viral Hepatitis A and B. , 2005, , 115-128.		1
402	Management of Hepatitis B in Liver Transplantation Patients. Seminars in Liver Disease, 2004, 24, 55-62.	3.6	60
403	Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. Nephrology Dialysis Transplantation, 2004, 19, 1779-1785.	0.7	38
404	Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transplant International, 2004, 17, 746-758.	1.6	17
405	Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. Transplant International, 2004, 17, 759-766.	1.6	11
406	Transplantation and prevention of reinfection. Current Hepatitis Reports, 2004, 3, 67-75.	0.3	1
407	No hepatic iron overload 12 years after liver transplantation for hereditary hemochromatosis. Hepatology, 2004, 40, 762-762.	7.3	12
408	Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transplantation, 2004, 10, 295-300.	2.4	65
409	Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transplantation, 2004, 10, 868-871.	2.4	32
410	Evolving strategies to prevent HBV recurrence. Liver Transplantation, 2004, 10, S74-S85.	2.4	84
411	Steroid withdrawal at day 14 after liver transplantation: A double-blind, placebo-controlled study. Liver Transplantation, 2004, 10, 1454-1460.	2.4	55
412	Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. Journal of Hepatology, 2004, 41, 446-453.	3.7	60
413	Treatment of patients with hepatic failure: the difficult place of liver support systems. Journal of Hepatology, 2004, 41, 694-695.	3.7	15
414	Place of the liver biopsy in liver transplantation. Journal of Hepatology, 2004, 41, 897-901.	3.7	10

#	ARTICLE	IF	CITATIONS
415	140 Influence of graft histologic lesions on recipient quality of life 10 years after liver transplantation. <i>Journal of Hepatology</i> , 2004, 40, 48-49.	3.7	0
416	157 Timing for liver transplantation in HIV coinfecting patients. <i>Journal of Hepatology</i> , 2004, 40, 53.	3.7	1
417	160 Severe primary HHV8 infection following transplantation with anti-HHV8-positive liver grafts. <i>Journal of Hepatology</i> , 2004, 40, 54.	3.7	0
418	265 HBV recurrence associated with HCC recurrence after liver transplantation: Role of HBV production from tumoral cells. <i>Journal of Hepatology</i> , 2004, 40, 83.	3.7	0
419	473 Compartmentalization of hepatitis C virus and response to therapy. <i>Journal of Hepatology</i> , 2004, 40, 140.	3.7	0
420	RESULTS OF LIS2T, A MULTICENTER, RANDOMIZED STUDY COMPARING CYCLOSPORINE MICROEMULSION WITH C2 MONITORING AND TACROLIMUS WITH C0 MONITORING IN DE NOVO LIVER TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, 1632-1638.	1.0	124
421	Adoptive transfer of immunity to HBV through liver graft: Does it prevent HBV recurrence?. <i>Hepatology</i> , 2003, 37, 16-18.	7.3	2
422	All liver recipients benefit from the protocol 10-year liver biopsies. <i>Hepatology</i> , 2003, 37, 1293-1301.	7.3	119
423	HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. <i>Hepatology</i> , 2003, 38, 86-95.	7.3	212
424	Fulminant hepatitis after grand mal seizures: Mechanisms and role of liver transplantation. <i>Hepatology</i> , 2003, 38, 443-451.	7.3	17
425	Viral and clinical factors associated with the fulminant course of hepatitis A infection. <i>Hepatology</i> , 2003, 38, 613-618.	7.3	176
426	Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 703-711.	2.4	84
427	Incidence of Renal and Liver Rejection and Patient Survival Rate Following Combined Liver and Kidney Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 348-356.	4.7	106
428	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. <i>Hepatology</i> , 2003, 38, 1419-1427.	7.3	190
429	Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. <i>Journal of Viral Hepatitis</i> , 2003, 10, 197-204.	2.0	19
430	Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. <i>Clinics in Liver Disease</i> , 2003, 7, 667-681.	2.1	7
431	Interferon- α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. <i>Gastroenterology</i> , 2003, 124, 642-650.	1.3	331
432	Extracorporeal liver support with MARS in liver failure: has it a role in the treatment of severe alcoholic hepatitis?. <i>Journal of Hepatology</i> , 2003, 38, 104-106.	3.7	7

#	ARTICLE	IF	CITATIONS
433	Liver transplantation in patients with HIV infection. <i>Journal of Hepatology</i> , 2003, 39, 3-6.	3.7	74
434	Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results. <i>Journal of Hepatology</i> , 2003, 39, 181-189.	3.7	37
435	Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. <i>Journal of Hepatology</i> , 2003, 39, 587-594.	3.7	142
436	Autoimmune liver disease as the main cause of cryptogenic cirrhosis in European patients who underwent liver transplantation. <i>Journal of Hepatology</i> , 2003, 38, 209-210.	3.7	0
437	Domino liver transplantation: A french experience. <i>Journal of Hepatology</i> , 2003, 38, 5.	3.7	0
438	Clinical and histological follow-up after liver transplantation (LT) for hereditary hemochromatosis (HH). <i>Journal of Hepatology</i> , 2003, 38, 38.	3.7	707
439	Indeterminate fulminant hepatitis: Clinico-pathological, immunological and virological reevaluation of the pre and post transplantation period of 31 cases transplanted since 1987. <i>Journal of Hepatology</i> , 2003, 38, 41-42.	3.7	0
440	Fatal disseminated kaposi sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. <i>Journal of Hepatology</i> , 2003, 38, 48.	3.7	0
441	Long term effect of liver transplantation (LT) on met 30 TTR familial amyloid polyneuropathy (FAP). <i>Journal of Hepatology</i> , 2003, 38, 48.	3.7	0
442	Pilot study of treatment with pegylated interferon and ribavirin in liver transplant recipients with hepatitis C infection. <i>Journal of Hepatology</i> , 2003, 38, 48-49.	3.7	0
443	A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. <i>Gut</i> , 2003, 52, 893-897.	12.1	177
444	Liver Resection as a Bridge to Transplantation for Hepatocellular Carcinoma on Cirrhosis. <i>Annals of Surgery</i> , 2003, 238, 508-519.	4.2	306
445	Bioartificial liver: present and future. <i>Transplantation</i> , 2003, 75, 1769-1770.	1.0	2
446	Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. <i>Transplantation</i> , 2003, 76, 1699-1704.	1.0	141
447	Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. <i>Gut</i> , 2002, 50, 95-99.	12.1	109
448	Prognostic Value of Quantitative Kaposi Sarcoma-associated Herpesvirus Load in Posttransplantation Kaposi Sarcoma. <i>Journal of Infectious Diseases</i> , 2002, 186, 110-113.	4.0	93
449	Decision for Retransplantation of the Liver. <i>Annals of Surgery</i> , 2002, 236, 713-721.	4.2	167
450	Liver transplantation in Italy. Letter to Italian friends. <i>Digestive and Liver Disease</i> , 2002, 34, 619-620.	0.9	6

#	ARTICLE	IF	CITATIONS
451	Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. <i>Gastroenterology</i> , 2002, 122, 923-930.	1.3	429
452	Cutaneous thrombotic microangiopathy during treatment with Alpha-interferon for chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 37, 871-872.	3.7	17
453	Sero-lymphotropic copartmentalization of hepatitis C virus quasispecies and severity of liver disease. <i>Journal of Hepatology</i> , 2002, 36, 17.	3.7	0
454	Liver transplantation in HIV-HCV coinfecting patients. New indication and preliminary experience. <i>Journal of Hepatology</i> , 2002, 36, 26-27.	3.7	1
455	Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. <i>Journal of Hepatology</i> , 2002, 36, 32.	3.7	9
456	Towards an extension of the indications of liver transplantation (LT) for hepatocellular carcinoma with cirrhosis?. <i>Journal of Hepatology</i> , 2002, 36, 33.	3.7	0
457	Retransplantation of the liver: a reappraisal in the era of combined organ shortage and economical constraints. <i>Journal of Hepatology</i> , 2002, 36, 34.	3.7	0
458	Level of replication and genotypes of hepatitis A virus in fulminant and non-fulminant hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 36.	3.7	0
459	Relationship between alcoholic relapse, non compliance and histological lesions after liver transplantation (LT) for alcoholic cirrhosis (AC). <i>Journal of Hepatology</i> , 2002, 36, 38.	3.7	1
460	Fulminant hepatitis consecutive to grand mal seizures: mechanisms, role of drugs, of hypoxemia and place of liver transplantation (LT). <i>Journal of Hepatology</i> , 2002, 36, 39.	3.7	0
461	Adefovir therapy for HBV infection after liver transplantation (LT). <i>Journal of Hepatology</i> , 2002, 36, 42.	3.7	1
462	Clinico-pathological, immunological and virological characteristics of patients transplanted for cryptogenic cirrhosis. <i>Journal of Hepatology</i> , 2002, 36, 50.	3.7	0
463	Clinical, biological, genetic characteristics and outcome of patients with severe form of Wilson disease (WD). <i>Journal of Hepatology</i> , 2002, 36, 188-189.	3.7	0
464	Treatment of patients with hepatic failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S274-S279.	2.8	3
465	Antituberculous drugs in patients with chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S408-S412.	2.8	10
466	Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection: Reliability of the 1999 Banff schema. <i>Hepatology</i> , 2002, 35, 117-125.	7.3	33
467	I favor therapy for hepatitis C virus recurrence after transplantation. <i>Liver Transplantation</i> , 2002, 8, S55-S58.	2.4	4
468	LIVER TRANSPLANTATION FOR FULMINANT HEPATIC FAILURE DUE TO COCAINE INTOXICATION IN AN ALCOHOLIC HEPATITIS C VIRUS-INFECTED PATIENT. <i>Transplantation</i> , 2002, 73, 157.	1.0	10

#	ARTICLE	IF	CITATIONS
469	NEUROLOGICAL IMPROVEMENT DURING BIOARTIFICIAL LIVER SESSIONS IN PATIENTS WITH ACUTE LIVER FAILURE AWAITING TRANSPLANTATION ¹ . <i>Transplantation</i> , 2002, 73, 257-264.	1.0	81
470	Decision for retransplantation of the liver: an experience- and cost-based analysis. <i>Annals of Surgery</i> , 2002, 236, 713-21; discussion 721.	4.2	60
471	Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. <i>Journal of Hepatology</i> , 2001, 34, 943-945.	3.7	27
472	Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2001, 35, 590-597.	3.7	170
473	Mortality and long term outcome of combined liver and kidney transplantations. <i>Transplantation Proceedings</i> , 2001, 33, 1179-1180.	0.6	8
474	Auxiliary Partial Orthotopic Versus Standard Orthotopic Whole Liver Transplantation for Acute Liver Failure. <i>Annals of Surgery</i> , 2001, 234, 723-731.	4.2	94
475	Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. <i>Blood</i> , 2001, 98, 1332-1338.	1.4	33
476	Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation. <i>Clinical Transplantation</i> , 2001, 15, 159-166.	1.6	14
477	Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen. <i>Journal of Medical Virology</i> , 2001, 65, 493-504.	5.0	11
478	Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. <i>Liver Transplantation</i> , 2001, 7, 556-558.	2.4	50
479	INFLUENCE OF LIVER HEPATITIS C VIRUS RNA AND HEPATITIS C VIRUS GENOTYPE ON FAS-MEDIATED APOPTOSIS AFTER LIVER TRANSPLANTATION FOR HEPATITIS C. <i>Transplantation</i> , 2000, 70, 1390-1396.	1.0	36
480	Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. <i>Journal of Viral Hepatitis</i> , 2000, 7, 87-92.	2.0	48
481	Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. <i>Hepatology</i> , 2000, 32, 1189-1195.	7.3	224
482	Fulminant Non-A-G Viral Hepatitis Leading to Liver Transplantation. <i>Archives of Internal Medicine</i> , 2000, 160, 388.	3.8	23
483	Hepatitis and solid organ transplantation. <i>Transplantation Proceedings</i> , 2000, 32, 454-457.	0.6	24
484	Financial cost analysis of hospital-care treatment of virus C cirrhosis: A multicentric study carried out on 267 consecutively patients in 1998. <i>Gastroenterology</i> , 2000, 118, A1435.	1.3	0
485	Domino liver transplants for metabolic disorders: Experience with familial amyloidotic polyneuro-pathy. <i>Journal of Hepatology</i> , 2000, 32, 27.	3.7	2
486	The quality of life 10 years after liver transplantation. <i>Journal of Hepatology</i> , 2000, 32, 49.	3.7	0

#	ARTICLE	IF	CITATIONS
487	Fulminant viral hepatitis A and B: Different clinical patterns, similar prognosis. <i>Journal of Hepatology</i> , 2000, 32, 54.	3.7	0
488	Risk factors and prognosis of fulminant hepatitis A. <i>Journal of Hepatology</i> , 2000, 32, 106.	3.7	0
489	Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. <i>Journal of the American College of Surgeons</i> , 1999, 189, 584-593.	0.5	116
490	â€œSilentâ€ presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. <i>Hepatology</i> , 1999, 30, 1144-1150.	7.3	99
491	Retransplantation of the liver for recurrent hepatitis B virus infection: The Paul Brousse experience. <i>Liver Transplantation</i> , 1999, 5, 166-174.	1.8	30
492	Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. <i>Journal of Hepatology</i> , 1999, 30, 131-141.	3.7	186
493	Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. <i>Journal of Hepatology</i> , 1999, 30, 1130-1137.	3.7	107
494	Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1999, 31, 584-592.	3.7	32
495	Recurrence of hepatitis C virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1999, 31, 217-221.	3.7	27
496	Rheumatic complications following liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 1717-1718.	0.6	15
497	European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. <i>Gastroenterology</i> , 1999, 117, 619-625.	1.3	345
498	Will transplantation of an hepatitis C â€infectiousâ€ graft improve the outcome of liver transplantation in HCV patients?. <i>Gastroenterology</i> , 1999, 117, 263-265.	1.3	17
499	Nonrandom Distribution of Hepatitis C Virus Quasispecies in Plasma and Peripheral Blood Mononuclear Cell Subsets. <i>Journal of Virology</i> , 1999, 73, 9213-9221.	3.4	105
500	Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression. <i>Liver Transplantation</i> , 1998, 4, 146-151.	1.8	22
501	Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. <i>Kidney International</i> , 1998, 54, 1311-1319.	5.2	61
502	What Should We Expect From a Bioartificial Liver In Fulminant Hepatic Failure?. <i>Artificial Organs</i> , 1998, 22, 26-31.	1.9	19
503	Tacrolimus (FK506)-Based Dual Versus Triple Therapy Following Liver Transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 1394-1396.	0.6	5
504	HISTOLOGICAL FEATURES PREDICTIVE OF RECURRENCE OF PRIMARY BILIARY CIRRHOSIS AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1998, 65, 1328-1333.	1.0	62

#	ARTICLE	IF	CITATIONS
505	Transfer of Symptomatic Peanut Allergy to the Recipient of a Combined Liver-And-Kidney Transplant. <i>New England Journal of Medicine</i> , 1997, 337, 822-825.	27.0	166
506	Experience in one center of combined kidney and liver transplantation in 22 patients: Incidence of graft rejection and long-term graft outcome. <i>Transplantation Proceedings</i> , 1997, 29, 243-244.	0.6	7
507	Assessment of the results of liver transplantation and definition of criteria for the evaluation of transplant centers. <i>Transplantation Proceedings</i> , 1997, 29, 456-458.	0.6	5
508	Long-term results of combined kidney and liver transplantation at one center. <i>Transplantation Proceedings</i> , 1997, 29, 2365-2366.	0.6	13
509	Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. <i>Journal of Hepatology</i> , 1997, 26, 228-235.	3.7	100
510	De novo and apparent de novo hepatitis B virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1997, 26, 517-526.	3.7	144
511	Hepatitis viruses and liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, S335-S341.	2.8	28
512	Prolonged interferon α therapy of hepatitis B virus-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 1997, 4, 21-26.	2.0	20
513	Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. <i>Hepatology</i> , 1997, 26, 1343-1350.	7.3	95
514	Liver transplantation in patients with acute liver failure: the European experience. , 1996, , 186-200.		3
515	Liver Transplantation in Europe for Patients with Acute Liver Failure. <i>Seminars in Liver Disease</i> , 1996, 16, 415-425.	3.6	130
516	Auxiliary Partial Orthotopic Liver Transplantation for Fulminant Hepatitis. <i>Annals of Surgery</i> , 1996, 224, 712-726.	4.2	89
517	Sclerosing Cholangitis Following Human Orthotopic Liver Transplantation. <i>American Journal of Surgical Pathology</i> , 1995, 19, 81-90.	3.7	76
518	THE USE OF ABO-INCOMPATIBLE GRAFTS IN LIVER TRANSPLANTATION. <i>Transplantation</i> , 1995, 59, 1124-1132.	1.0	128
519	Combined liver and kidney transplantation in patients with chronic nephritis associated with end-stage liver disease. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 129-133.	0.7	30
520	Orthotopic Liver Transplantation in Fulminant and Subfulminant Hepatitis The Paul Brousse Experience. <i>Annals of Surgery</i> , 1995, 222, 109-119.	4.2	275
521	Liver transplantation for hepatitis B virus infection. <i>Liver Transplantation</i> , 1995, 1, 270-274.	1.8	9
522	Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. <i>Hepatology</i> , 1995, 21, 333-339.	7.3	152

#	ARTICLE	IF	CITATIONS
523	Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. <i>Hepatology</i> , 1995, 21, 929-932.	7.3	75
524	An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. <i>Hepatology</i> , 1995, 22, 1084-1089.	7.3	226
525	Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. <i>Gastroenterology</i> , 1995, 108, 1088-1096.	1.3	296
526	Liver transplantation for severe acute liver failure after herbal medicine. <i>Journal of Hepatology</i> , 1995, 22, 597.	3.7	72
527	Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. <i>Hepatology</i> , 1995, 21, 333-339.	7.3	10
528	Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. <i>Hepatology</i> , 1995, 21, 929-932.	7.3	5
529	Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. <i>Hepatology</i> , 1994, 19, 6-12.	7.3	63
530	The course of hepatitis C virus infection after liver transplantation. <i>Hepatology</i> , 1994, 20, 1137-1143.	7.3	236
531	â€œEUROHEPâ€™ consensus report on the management of liver transplantation for hepatitis B virus infection. <i>Journal of Hepatology</i> , 1994, 21, 1140-1143.	3.7	65
532	The course of hepatitis C virus infection after liver transplantation*1. <i>Hepatology</i> , 1994, 20, 1137-1143.	7.3	227
533	Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. <i>Journal of Hepatology</i> , 1993, 18, 119-122.	3.7	60
534	Liver transplantation in cirrhosis due to hepatitis D virus infection. <i>Journal of Hepatology</i> , 1993, 17, S154-S156.	3.7	7
535	Liver Transplantation in European Patients with the Hepatitis B Surface Antigen. <i>New England Journal of Medicine</i> , 1993, 329, 1842-1847.	27.0	1,015
536	Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. <i>Gastroenterology</i> , 1993, 104, 549-555.	1.3	236
537	HCV type II has a more pathogenic course after liver transplantation. <i>Hepatology</i> , 1993, 18, A59.	7.3	13
538	Clinical implications of the quantitation of HCV RNA in liver transplantation. <i>Hepatology</i> , 1993, 18, A71.	7.3	1
539	LIVER TRANSPLANTATION FOR HEPATITIS B. <i>Gastroenterology Clinics of North America</i> , 1993, 22, 271-283.	2.2	18
540	Fipexide-induced fulminant hepatitis. <i>Journal of Hepatology</i> , 1992, 15, 144-146.	3.7	23

#	ARTICLE	IF	CITATIONS
541	PERSISTENT HEPATITIS B VIRUS INFECTION OF MONONUCLEAR BLOOD CELLS WITHOUT CONCOMITANT LIVER INFECTION. <i>Transplantation</i> , 1990, 49, 1155-1157.	1.0	168
542	FINE-NEEDLE ASPIRATION BIOPSY OF HUMAN LIVER ALLOGRAFTS. <i>Transplantation</i> , 1990, 50, 704-706.	1.0	9
543	Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. <i>Journal of Hepatology</i> , 1990, 11, 102-110.	3.7	20
544	Liver Transplantation for Protoporphyrin. <i>Gastroenterology</i> , 1988, 95, 816-819.	1.3	69